Axsome acquires Avenue's subsidiary for epilepsy drug development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. GMAB
6. CART
7. FFAI
8. FFR
9. AZN
10. FICO

Go back to Axsome acquires Avenue's subsidiary for epilepsy drug development

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

November 6, 2025 7:00 AM EST

Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (Avenue or the Company), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (Baergic), today announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), including... More